ESMO WCGIC 2023 | Sequencing treatment options for HCC

Lorenza Rimassa, MD, Humanitas University and IRCCS Humanitas Research Hospital Rozzano, Milan, Italy, discusses the process of treating patients with hepatocellular carcinoma (HCC). Patients have the options of atezolizumab plus bevacizumab or durvalumab plus tremelimumab, and whilst these regimens have been tested in Phase III trials versus sorafenib, a cross trial comparison cannot be conducted. Dr Rimassa additionally highlights the absence of a suitable biomarker. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.